---All---
  • ---All---
  • Accession
  • Catalog #

Kallikrein 6 Antibody (N-term)Purified Rabbit Polyclonal Antibody (Pab)

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AP6325a 0.1 mg 400 ul In Stock $ 255.00 Add to cart
AP6325a-ev20 20 ug 100 ul In Stock $ 95.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

Kallikrein 6 Antibody (N-term) - Product info

ApplicationWB, IHC, FC
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionQ92876
ReactivityHuman
Concentration0.25 mg/ml
IsotypeRabbit Ig
Calculated MW26856 Da

Kallikrein 6 Antibody (N-term) - Additional info

Gene ID 5653
Other Names
KLK6; PRSS18; PRSS9; Kallikrein-6; Neurosin; Protease M; SP59; Serine protease 18; Serine protease 9; Zyme
Target/Specificity
This Kallikrein 6 Antibody antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 6~35 amino acids from the N-terminal region of human KLK6.
Dilution
WB~~1:50~100
IHC~~1:10~50
FC~~1:10~50
Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
Kallikrein 6 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Kallikrein 6 Antibody (N-term) - Protein Information

Name KLK6
Synonyms PRSS18, PRSS9
Function
Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis
Cellular Location
Secreted. Nucleus, nucleolus. Cytoplasm. Mitochondrion. Microsome. Note=In brain, detected in the nucleus of glial cells and in the nucleus and cytoplasm of neurons Detected in the mitochondrial and microsomal fractions of HEK-293 cells and released into the cytoplasm following cell stress
Tissue Location
In fluids, highest levels found in milk of lactating women followed by cerebrospinal fluid, nipple aspirate fluid and breast cyst fluid. Also found in serum, seminal plasma and some amniotic fluids and breast tumor cytosolic extracts. Not detected in urine. At the tissue level, highest concentrations found in glandular tissues such as salivary glands followed by lung, colon, fallopian tube, placenta, breast, pituitary and kidney. Not detected in skin, spleen, bone, thyroid, heart, ureter, liver, muscle, endometrium, testis, pancreas, seminal vesicle, ovary, adrenals and prostate. In brain, detected in gray matter neurons (at protein level). Colocalizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions Overexpressed in primary breast tumors but not expressed in metastatic tumors

Kallikrein 6 Antibody (N-term) - Related products

AP6325a: Kallikrein 6 Antibody (N-term)

AP6325b: Kallikrein 6 Antibody (Center)

RI12932: KLK6 predesign siRNA

DC04116: Human KLK6 cDNA Clone

LY10771a: KLK6 Over-expression Lysate

AT2641a: KLK6 Antibody (monoclonal) (M01)

Kallikrein 6 Antibody (N-term) - Application data

  • Western blot analysis of KLK6 (arrow) using rabbit polyclonal KLK6 Antibody (A13) (Cat. #AP6325a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the KLK6 gene.

  • Kallikrein 6(KLK6) Antibody (N-term) (Cat. #AP6325a)immunohistochemistry analysis in formalin fixed and paraffin embedded human breast carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Kallikrein 6(KLK6) Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

  • Kallikrein 6 (KLK6) Antibody (N-term) (Cat. #AP6325a) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Kallikrein 6 Antibody (N-term) - Research Areas

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. The KLK6 enzyme is regulated by steroid hormones. In tissue culture, the enzyme has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer's disease.

REFERENCES

Christophi, G.P., et al., J. Neurochem. 91(6):1439-1449 (2004). Bayes, A., et al., Biol. Chem. 385(6):517-524 (2004). Pampalakis, G., et al., Biochem. Biophys. Res. Commun. 320(1):54-61 (2004). Ghosh, M.C., et al., Tumour Biol. 25(4):193-199 (2004). Sauter, E.R., et al., Int. J. Cancer 108(4):588-591 (2004).